The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be (link sends e-mail)
| Study Title | A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY® Study) |
|---|---|
| Study Drug | BI 1291583 |
| Type of Study Drug | Anti-inflammatory |
| Study Phase | 3 |
| Study Sponsor | Boehringer Ingelheim |
| Link in registry(ies) | |
| Participating ECFS-CTN sites | Please contact ECFS-CTN@uzleuven.be (link sends e-mail) for most recent sitelist |
| Age | Pediatric and Adult patients |